{"id":"sage-547","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Bradycardia"},{"rate":"5-10%","effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the GABA_A receptor alpha 1 subunit, SAGE-547 aims to increase the expression of the alpha 1 subunit, which can help to reduce seizure activity. This is particularly relevant for the treatment of status epilepticus, a severe and life-threatening form of epilepsy. The antisense oligonucleotide mechanism allows for a targeted and specific approach to modulating the GABA_A receptor, which can help to reduce the risk of adverse effects.","oneSentence":"SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:13.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Status epilepticus"}]},"trialDetails":[{"nctId":"NCT06979544","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2025-06-16","conditions":"Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD)","enrollment":90},{"nctId":"NCT05329779","phase":"PHASE4","title":"Study on Allopregnanolone and Depression in Perimenopausal Women","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-04","conditions":"Depression","enrollment":2},{"nctId":"NCT07079761","phase":"PHASE2","title":"Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-08-04","conditions":"Post Traumatic Stress Disorder","enrollment":96},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT02477618","phase":"PHASE3","title":"A Study With SAGE-547 for Super-Refractory Status Epilepticus","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2015-06","conditions":"Super-Refractory Status Epilepticus","enrollment":132},{"nctId":"NCT02942004","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-08-01","conditions":"Postpartum Depression","enrollment":138},{"nctId":"NCT05223829","phase":"PHASE1","title":"Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2023-08-01","conditions":"PTSD, Alcohol Use Disorder","enrollment":25},{"nctId":"NCT03665038","phase":"PHASE3","title":"A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2018-09-07","conditions":"Post Partum Depression","enrollment":28},{"nctId":"NCT02433314","phase":"","title":"An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus","status":"NO_LONGER_AVAILABLE","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"","conditions":"Super-Refractory Status Epilepticus","enrollment":""},{"nctId":"NCT02285504","phase":"PHASE2","title":"Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2015-01-07","conditions":"Postpartum Depression","enrollment":4},{"nctId":"NCT05645432","phase":"PHASE2","title":"An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2023-05-10","conditions":"Tinnitus","enrollment":10},{"nctId":"NCT02052739","phase":"PHASE1, PHASE2","title":"Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2014-03-21","conditions":"Super-refractory Status Epilepticus","enrollment":25},{"nctId":"NCT02614547","phase":"PHASE2","title":"A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2015-12-15","conditions":"Severe Postpartum Depression","enrollment":21},{"nctId":"NCT05059600","phase":"PHASE4","title":"A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2021-10-08","conditions":"Postpartum Depression","enrollment":52},{"nctId":"NCT02942017","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-07","conditions":"Postpartum Depression","enrollment":108},{"nctId":"NCT03924492","phase":"","title":"Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression","status":"APPROVED_FOR_MARKETING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"","conditions":"Postpartum Depression","enrollment":""},{"nctId":"NCT06580444","phase":"PHASE2","title":"Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study","status":"NOT_YET_RECRUITING","sponsor":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","startDate":"2025-07-28","conditions":"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","enrollment":40},{"nctId":"NCT04468360","phase":"PHASE2","title":"Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-03-04","conditions":"Post Traumatic Stress Disorder","enrollment":256},{"nctId":"NCT05543746","phase":"","title":"Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-08-05","conditions":"Postpartum Depression","enrollment":10},{"nctId":"NCT05314153","phase":"EARLY_PHASE1","title":"Effects Zulresso on Postpartum Psychosis","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-02-23","conditions":"Postpartum Psychosis","enrollment":10},{"nctId":"NCT05254405","phase":"PHASE4","title":"An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder","status":"RECRUITING","sponsor":"Donald Jeffrey Newport","startDate":"2023-06-01","conditions":"Post-Traumatic Stress Disorder","enrollment":20},{"nctId":"NCT04537806","phase":"PHASE3","title":"A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)","status":"TERMINATED","sponsor":"Sage Therapeutics","startDate":"2020-12-18","conditions":"Acute Respiratory Distress Syndrome, COVID-19","enrollment":29},{"nctId":"NCT02277106","phase":"PHASE2","title":"Evaluate SAGE-547 in Participants With Essential Tremor","status":"COMPLETED","sponsor":"Sage Therapeutics","startDate":"2014-09-23","conditions":"Essential Tremor","enrollment":25},{"nctId":"NCT04273191","phase":"PHASE4","title":"A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)","status":"WITHDRAWN","sponsor":"Sage Therapeutics","startDate":"2020-02","conditions":"Postpartum Depression","enrollment":""},{"nctId":"NCT02603926","phase":"PHASE2","title":"Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone","status":"COMPLETED","sponsor":"Randi J. Hagerman, MD","startDate":"2015-10","conditions":"Fragile X-associated Tremor/Ataxia Syndrome","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SAGE-547","genericName":"SAGE-547","companyName":"Supernus Pharmaceuticals, Inc.","companyId":"supernus-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit. Used for Status epilepticus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}